OncoGenex Pharmaceuticals, Inc. (OGXI)
Oncology Corporate Profile
- Products & Overview
- Recent News
HQ Location
1522 217th Place SE, Suite 100Bothell, WA 98021
Company Description
OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development.
Website: http://www.oncogenex.com/
Commercial Products
This company does not have any commercial productsPipeline Products
- Brand
- Generic
- Investigational
| Brand / Product | Class | Area of Study | Phase | Partnership |
|---|---|---|---|---|
| OGX-011/TV-1011 (+ docetaxel) | clusterin inhibitor | 2nd line metastatic Hormone refractory Prostate cancer (HRPC) | III | Teva |
| OGX-011/TV-1011 | clusterin inhibitor | Advanced Non Small Cell Lung Cancer (NSCLC) | II | Teva |
| OGX-011/TV-1011 | clusterin inhibitor | Breast cancer | II | Teva |
| SN2310 | copoisonerase inhibitor | Various cancer types | I | |
| OGX-427 | Hsp27 inhibitor | Various cancer types | I | |
| CSP-9222 | apoptosis inducer (caspase activator) | Various cancer types | Preclinical | |
| OGX-225 | insulin-like growth factor-1 receptor (IGF-1R) inhibitor (IGFBP-2 and IGFBP-5 inhibitor) | Various cancer types | Preclinical |
View additional information on product candidates here »
Recent News Headlines
[PR Newswire] - OncoGenex Pharmaceuticals, Inc. , announced today that the Company has appointed Mr. David V. Smith to its board of directors. Mr. Smith brings to the board substantial financial expertise in financial controls, analytics and process.
[PR Newswire] - OncoGenex Pharmaceuticals, Inc. announced today that the Company's second quarter financial results will be released on Thursday, August 5, 2010, and that the Company will host a conference call and live webcast at 4:30 p.m.
[at MarketWatch] - Israeli stocks rise for a third day Monday, led by strength in Israel Chemicals, Teva Pharmaceutical and the real estate stocks.
[PR Newswire] - OncoGenex Pharmaceuticals, Inc. announced today the initiation of a Phase 3 registration trial of custirsen sodium , its lead product candidate being developed for the treatment of castrate-resistant prostate cancer .
(Puget Sound Business Journal) June 21, 2010 - OncoGenex Pharmaceuticals Inc. said it’s begun testing its drug aimed at treatment of castrate-resistant prostate cancer.
(MSN Money) June 7, 2010 - OncoGenex Pharmaceuticals, Inc. today announced final results from a Phase 1 trial. The primary purpose of this trial was to evaluate the safety and tolerability of OGX-427 up to doses of 1000 mg for the treatment of various solid tumors.
[PR Newswire] - OncoGenex Pharmaceuticals, Inc. announced today that Scott Cormack, OncoGenex's President and Chief Executive Officer, will present at the 9th Annual Needham Healthcare Conference on June 10 at 10:40 a.m.
Medical radiation equipment maker Accuray Inc. said Wednesday it named Jack Goldstein to its board of directors. Goldstein is currently an independent consultant and most recently worked as president and chief operating officer of Chiron Corp. from 2004 to 2006.
OncoGenex Pharmaceuticals, Inc. announced today that Scott Cormack, OncoGenex's President and Chief Executive Officer, will present at the 6th Annual Rodman and Renshaw Global Healthcare Conference on May 17 at 4:30 p.m.
OncoGenex Pharmaceuticals, Inc. announced today that the Company's first quarter financial results will be released on Thursday May 6, 2010, and that the Company will host a conference call and live webcast at 4:30 p.m.